Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that new data was presented at the European Society of Breast Imaging ("EUSOBI") Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD, principal investigator of the independent, non-sponsored study.

Related Keywords

Spain ,Israel ,China ,Israeli ,Todd Kehrli ,Michael Polyviou ,Eyal Shamir ,Company Annual Report On Form ,University Hospital Lucus Augusti ,Breast Unit ,University Hospital Lucus ,Cure Medical ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Breast Cancer ,Ucía Grana López ,Tumor Removal ,Real Alternative ,Surgery ,Kryoablation ,Rana López ,Icecure Medical Ltd ,Alternative Treatment ,